Table 2.
Evidence-based recommendations for antiviral prophylaxis in patients with solid tumours and haematological malignancies except hepatitis B
| Chemotherapy | Rituximab | Alemtuzumab | Proteasome inhibitors | Purine analogues | Autologous SCT | |
|---|---|---|---|---|---|---|
| HSV/VZV | None (CII) | None (CII) | Acyclovir (AII) | Acyclovir (AII) | Acyclovira (AII) | None (CII) |
| Influenza | Vaccination (AII) | Vaccination (BIII) | Vaccination (BIII) | Vaccination (AIII) | Vaccination (BIII) | Vaccination (BIII) |
| CMV | None (CII) | None (CII) | None (BII) | None (CIII) | None (CIII) | None (CII) |
| EBV | None (EIII) | None (EIII) | None (EIII) | None (EIII) | None (EIII) | None (EIII) |
| Resp. viruses adenovirus | None (CII) | None (CII) | None (CII) | None (CII) | None (CII) | None (CII) |
| HCV | None (CII) | None (CII) | None (CII) | None (CII) | None (CII) | None (CII) |
aIn the presence of risk factors: second-line therapy, prolonged treatment with steroids, CD4 count <50/μl, age >65 years, neutrophil count <1000/μ